March 15 at 4:30 p.m.
Filed under:
Chicago executives,
Pharmaceuticals
By Bruce Japsen
Abbott Laboratories Chairman and Chief Executive Miles White received a 2 percent raise last year, to $1.89 million, though his bonus and other stock awards dipped amid a turbulent year for the North Chicago-based drug and medical product giant.
Abbott, which failed to win Food and Drug Administration approval for certain prescription drugs, valued White’s total compensation package at nearly $25.6 million in 2010, down from $26.2 million in 2009, according to the company’s annual proxy statement filed Tuesday afternoon with the Securities and Exchange Commission.. The total includes stock awards, bonus, salary and other compensation. Get the full story »
Aug. 25, 2010 at 11:49 p.m.
Filed under:
International,
Pharmaceuticals
By Dow Jones Newswires-Wall Street Journal
India’s market leader in medicines will soon be based near Lake Michigan.
Abbott Laboratories will hold the biggest share of India’s pharmaceuticals market, about 7 percent, when the company closes as early as next month on a $3.7 billion takeover of the drugs business of Piramal Healthcare Ltd. After committing more than $10 billion since February on such deals, Abbott Chief Executive Miles White said he has assembled a business in fast-growing countries that the company will count on for a big part of its growth. Get the full story »
April 23, 2010 at 11:31 a.m.
Filed under:
Corporate governance,
Earnings,
Economy,
Health care
By Wailin Wong | Abbott Laboratories shareholders voted down two proposals seeking
greater participation in corporate governance issues at the North
Chicago company’s annual meeting.
A “say on pay” proposal, which would have allowed shareholders to hold a
yearly advisory vote about senior executive compensation, was defeated
after garnering 41 percent approval, according to a preliminary tally. A
second proposal that would have given shareholders owning more than 10
percent of common stock the ability to convene a special meeting was
also defeated after reaching just 38 percent approval.
Get the full story »
